- Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress
- Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
- Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
- Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
- Shattuck Labs Announces Participation in Upcoming March Conferences
- Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
- Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
- Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Thursday, Shattuck Labs Inc (STTK:NSQ) closed at 7.49, -36.31% below its 52-week high of 11.76, set on May 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.65 |
---|---|
High | 7.68 |
Low | 7.20 |
Bid | 7.10 |
Offer | 7.80 |
Previous close | 7.63 |
Average volume | 519.76k |
---|---|
Shares outstanding | 47.55m |
Free float | 41.21m |
P/E (TTM) | -- |
Market cap | 362.81m USD |
EPS (TTM) | -1.93 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼